NantKwest Names Angela Wilson Chief Financial Officer
17 11월 2015 - 8:00PM
Business Wire
NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy
company focused on harnessing the power of the innate immune system
by using natural killer cells to treat cancer, infectious diseases
and inflammatory diseases, today announced the appointment of
Angela Wilson as chief financial officer (CFO). She succeeds
Richard Gomberg, who served as the company’s CFO since January 2010
as an independent contractor.
“Angie is an accomplished senior financial executive with
extensive healthcare industry experience,” said Patrick
Soon-Shiong, M.D., chairman and chief executive officer of
NantKwest. “For more than 20 years, she has provided senior-level
financial, accounting and tax services to public companies. Angie
brings a deep understanding of operations and transactions, public
offerings, business combinations, Sarbanes-Oxley compliance and
strategic business planning. We welcome Angie and look forward to
her insights and contributions.”
Wilson, a certified public accountant (CPA), first joined
NantKwest in October 2015 as vice president, finance. Previously,
Wilson served as vice president, finance and controller for Virgin
Galactic, hired to prepare the company for an initial public
offering. She began her professional career and served for 18 years
with Ernst & Young (EY), a multinational professional services
firm. At E&Y, she rose through the auditing ranks, most
recently serving as audit partner, primarily working with
biotechnology, pharmaceutical and healthcare companies. Wilson
earned a master of business administration (MBA) degree from
Arizona State University and a bachelor in accounting degree, summa
cum laude, from the University of Tulsa.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact; (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody; and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
“cytokine storms” reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest’s NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest’s NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information please
visit http://www.nantkwest.com and follow Dr. Soon-Shiong on
Twitter@solvehealthcare.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151117005639/en/
NantKwestJen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024